Mazdutide

Vialdyne buyer fit

Overview

Mazdutide, carrying development codes IBI362 (Innovent) and LY3305677 (Eli Lilly), is an investigational dual co-agonist hitting both the GLP-1 receptor and the glucagon receptor. Receptor scope is what marks it inside the multi-agonist landscape: it sits between the GIP/GLP-1 dual agonist Tirzepatide and the GIP/GLP-1/glucagon tri-agonist Retatrutide, engaging the GLP-1 and glucagon arms only, with no GIP component. This positioning makes the molecule the right tool when research needs to isolate the glucagon-pathway contribution from the GIP contribution inside the dual / tri-agonist family. Development is led by Innovent Biologics in China under license from Eli Lilly, currently in the Phase 3 DREAMS program for chronic weight management and T2DM; Chinese NMPA approval is on a faster track than Western markets. For research and pre-clinical buyers, Vialdyne releases Mazdutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The batch COA covers RP-HPLC peak integration, ESI-MS identity, Karl Fischer water, and counter-ion quantitation. LC-MS/MS sequence verification is available when required by an agreed pharmacy qualification protocol: the close structural similarity within the dual-agonist class means cross-supplier identity confusion is an operationally real risk if mass-spec is the only identity gate. The 10 mg standard fill fits bench-scale aliquot work; larger fills for extended programs are scoped under change-control.

Applications & buyer fit

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

2259884-03-0

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1075.7 hours

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Mazdutide; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Mazdutide

VD260428-MX133 · 99.31%

Regulatory note

Not yet approved as a finished drug at the time of writing, this is an investigational compound in Phase 3 development under Innovent / Eli Lilly. It is supplied for research use only. Any commonly cited CAS should be confirmed against the batch COA.

Selected literature

1. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225.
2. Zhu D, Zhao J, Qian L, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652:172-180 (DREAMS-1).
3. Guo L, Zhang B, Yang W, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652:181-188 (DREAMS-2).
4. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14:8289.
5. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691.
6. Azam MH, Azam MH, Azam KU, et al. Efficacy and safety of mazdutide in managing overweight and obesity among non-diabetic adults: a meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):4464-4473.

Frequently asked questions